Up to one month of treatment with inhaled vancomycin, the antibiotic of choice for treating most methicillin-resistant Staphylococcus aureus (MRSA) infections, together with a combination of oral and topical antibiotics, failed to clear infection in cystic fibrosis (CF) patients at better rates than the antibiotic combination alone, results from a Phase 2 clinical…
News
Blood levels of D-lactate may be markers of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF), according to preliminary data from a new study. The research, “Serum Level of D-Lactate in Patients with Cystic Fibrosis: Preliminary Data,” was published in the journal…
Single nucleotide polimorphisms (or variants), known as SNPs — the most common type of genetic variation — in the SLC26A9 gene are linked to poorer lung responses to Kalydeco in cystic fibrosis (CF) patients, a French study reports. The study, “SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With…
Attain Health will partner with DarioHealth, a digital health and big data solutions company, to test its Dario Engage platform to monitor blood sugar levels in cystic fibrosis (CF) patients with CF-related diabetes (CFRD). Attain Health provides integrative health coaching for CF patients. CFRD is an unusual form…
Analysis of blood glucose levels in cystic fibrosis (CF) patients being treated with Orkambi (ivacaftor/lumacaftor) shows that the therapy has minimal impact on glycemic control, a small study reports. Up to 50 percent of adults with cystic fibrosis develop diabetes, making so-called CF-related diabetes (CFRD) the most common comorbidity,…
ELITechGroup Biomedical Systems has released a new, advanced version of its Macroduct system, called the Macroduct Advanced Sweat Collection System, which allows for improved standardized sweat testing for the diagnosis of cystic fibrosis. The Macroduct Advanced Sweat Collection System has been cleared by the U.S Food and Drug…
Orkambi (lumacaftor/ivacaftor), a treatment for cystic fibrosis (CF) patients in Australia age 6 and up, is closer to being subsidized by the government, according to Vertex Pharmaceuticals, the medication’s manufacturer. The company received a recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC), an independent expert body, to list…
When Shira Zagury joined the Cystic Fibrosis Foundation of Israel as CEO eight years ago, only one cystic fibrosis (CF) patient sat on the nine-member board of directors. Today, five of the nine are adults with CF — a reflection of the ever-increasing life expectancy of those born with the disease.
The U.S. Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) as the first-ever therapy to treat the underlying cause of cystic fibrosis (CF) in 1-year-old toddlers, Vertex Pharmaceuticals announced. “Parents and physicians now have a medicine to treat the underlying cause of CF in patients as young as one…
A study in mice showed it is possible to transplant stem cells into the lungs and replenish the airways with healthy cells, an approach that could combat cystic fibrosis and alleviate its symptoms. Researchers used stem cells from the airways of cystic fibrosis (CF) patients, which were corrected to produce…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.